We explore hNav1.9's unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors.
Validated pharmacology assays against both human and rat NaV1.9 channels are presented in our poster ‘Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery’.
Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery. Stable multi-species NaV1.9 assay systems remain rare, but they are essential for understanding how compounds perform from preclinical models through to human targets. Contact us to learn more.
 |  |
 |  |
We explore hNav1.9's unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors.
Development of a robust hNaV1.9 high-throughput screening assay on the Sophion Qube384 platform. This is complemented by a suite of ion channel selectivity assays and sensory neuron recordings to create a versatile screening cascade to support NaV1.9 drug discovery programmes.